
Medically Reviewed By
Dr. Neha Gupta ( Medical Oncology)
A comprehensive medical oncology guide on advanced Clear Cell Renal Cell Carcinoma (ccRCC), evaluating IMDC risk stratification (favorable vs intermediate/poor), dual checkpoint blockade (Nivolumab + Ipilimumab), and immuno-oncology TKI combinations (Pembrolizumab + Axitinib, Cabozantinib + Nivolumab).
CRITICAL CLINICAL RED FLAG: The classic triad of renal cell carcinoma—painless gross hematuria (blood in urine), flank pain, and a palpable abdominal mass—is a late presentation; microscopic hematuria or unprovoked hypertension requires prompt ultrasound and contrast CT imaging.
The International Metastatic RCC Database Consortium (IMDC) prognostic model incorporates six clinical factors: time from diagnosis to treatment <1 year, Karnofsky performance status <80%, baseline hemoglobin <LLN, serum calcium >ULN, neutrophil count >ULN, and platelet count >ULN.
Favorable Risk (0 factors): Slower biology, exceptionally responsive to IO-TKI combinations (Pembrolizumab + Axitinib / Lenvatinib + Pembrolizumab).
Intermediate & Poor Risk (1 to 6 factors): High-risk aggressive disease where Dual Immunotherapy (Nivolumab + Ipilimumab - CheckMate 214) provides long-term overall survival superiority.
Clear cell RCC is heavily driven by VHL gene inactivation, resulting in continuous HIF-1alpha accumulation and VEGF overproduction:
Anti-CTLA-4 (Ipilimumab): Expands novel antigen-specific T-cell clones in lymph nodes.
Anti-PD-1 (Nivolumab / Pembrolizumab): Reactivates exhausted effector T-cells in the renal tumor microenvironment.
VEGFR TKIs (Cabozantinib / Axitinib / Lenvatinib): Normalize tumor vasculature, reverse immune-suppressive myeloid cells, and block MET/AXL escape pathways.
"Dual immunotherapy induces deep and durable complete responses in over 10% of patients with metastatic kidney cancer, with remissions enduring years after stopping treatment." — Dr. Neha Gupta

Routine monitoring of thyroid-stimulating hormone (TSH), free T4, early morning cortisol, and liver transaminases at every cycle allows early hormonal replacement or corticosteroid intervention.
CLINICAL CAUTION: Percutaneous core biopsy of small solid renal masses is indicated prior to systemic therapy, but for clearly resectable localized masses, upfront robotic partial nephrectomy without biopsy remains standard.
In select patients with excellent performance status and solitary or low-volume metastases, upfront or deferred cytoreductive nephrectomy eliminates local pain, bleeding, and the source of immunosuppressive cytokines.
1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (CheckMate 214) — NEJM, 2018; 378: 1277-1290.
2. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (KEYNOTE-426) — Lancet Oncol, 2020; 21(5): 698-709.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

13+ Years Experience
Spica — Grover Hospital
Request a priority OPD appointment or second opinion on your scans.
Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.
Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.
Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.
Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.
South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.
Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.
Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.
Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi


Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
16+ Yrs ExpSenior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)
Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.
Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.
Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.